Segment Data (Tables)

3 Months Ended

Dec. 31, 2022

Segment Reporting [Abstract]

Revenue from External Customers by Geographic Area

Revenues by segment, organizational unit and geographical areas for the three-month periods are detailed below. The Company has no material intersegment revenues.

	Three Months Ended December 31,
(Millions of dollars)	2022						2021
	United States		International		Total		United States		International		Total
Medical
Medication Delivery Solutions (a)	$	620	$	419	$	1,039	$	620	$	476	$	1,096
Medication Management Solutions	564		142		706		484		143		627
Pharmaceutical Systems (a)	119		290		409		102		294		397
Total segment revenues	$	1,303	$	852	$	2,154	$	1,207	$	913	$	2,120
Life Sciences
Integrated Diagnostic Solutions	$	508	$	445	$	952	$	615	$	530	$	1,145
Biosciences	137		212		349		129		209		338
Total segment revenues	$	645	$	657	$	1,302	$	744	$	739	$	1,483
Interventional
Surgery	$	287	$	76	$	363	$	281	$	80	$	361
Peripheral Intervention	236		197		433		217		197		413
Urology and Critical Care	259		74		333		254		87		340
Total segment revenues	$	782	$	347	$	1,129	$	752	$	363	$	1,115
Total revenues from continuing operations	$	2,730	$	1,856	$	4,586	$	2,703	$	2,016	$	4,718

(a)Certain prior-period amounts were recast to reflect former intercompany transactions with Embecta.

Financial Information for Company's Segments

Segment income for the three-month periods was as follows:

	Three Months Ended December 31,
(Millions of dollars)	2022		2021
Income from Continuing Operations Before Income Taxes
Medical	$	554	$	572
Life Sciences	433		534
Interventional	301		265
Total Segment Operating Income	1,288		1,371
Acquisition-related integration and restructuring expense	(44)		(34)
Net interest expense	(96)		(96)
Other unallocated items (a)	(667)		(642)
Total Income from Continuing Operations Before Income Taxes	$	481	$	600

(a)Primarily comprised of foreign exchange, certain general and administrative expenses and share-based compensation expense.